The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies
- PMID: 15977997
- DOI: 10.2174/1566524054022585
The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies
Abstract
The capsule of Cryptococcus neoformans, the principal virulence factor of this fungus, is composed primarily of polysaccharide. The predominant component of the polysaccharide capsule is glucuronoxylomannan (GXM), a compound with potent immunoregulatory properties. GXM is bound and internalized by natural immune cells affecting innate and subsequent adaptive immune response. The cellular pattern recognition receptors involved in GXM binding include toll-like receptor (TLR)4, CD14, TLR2, CD18, Fc gamma receptor II (FcgammaRPi). This multiple cross-linking leads to a suppressive outcome that is arrested and even reversed by protective antibodies to GXM. This review analyzes the immunosuppressive effects induced by capsular material, considering its pattern recognition receptors, and dissects the mechanism of monoclonal antibody shifting to immunoactivation.
Similar articles
-
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.Infect Immun. 2004 Jun;72(6):3674-9. doi: 10.1128/IAI.72.6.3674-3679.2004. Infect Immun. 2004. PMID: 15155683 Free PMC article.
-
Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.Infect Immun. 1995 Aug;63(8):3005-14. doi: 10.1128/iai.63.8.3005-3014.1995. Infect Immun. 1995. PMID: 7622223 Free PMC article.
-
Receptor-mediated recognition of Cryptococcus neoformans.Nihon Ishinkin Gakkai Zasshi. 2002;43(3):133-6. doi: 10.3314/jjmm.43.133. Nihon Ishinkin Gakkai Zasshi. 2002. PMID: 12145626 Review.
-
Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.Mol Cell Probes. 1989 Dec;3(4):345-61. doi: 10.1016/0890-8508(89)90014-5. Mol Cell Probes. 1989. PMID: 2482437
-
Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.Trends Microbiol. 2001 Sep;9(9):445-51. doi: 10.1016/s0966-842x(01)02134-5. Trends Microbiol. 2001. PMID: 11553457 Review.
Cited by
-
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.Infect Immun. 2007 Jun;75(6):2729-39. doi: 10.1128/IAI.00094-07. Epub 2007 Mar 19. Infect Immun. 2007. PMID: 17371865 Free PMC article.
-
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.Eukaryot Cell. 2007 Jan;6(1):95-109. doi: 10.1128/EC.00306-06. Epub 2006 Nov 17. Eukaryot Cell. 2007. PMID: 17114596 Free PMC article.
-
The still obscure attributes of cryptococcal glucuronoxylomannan.Med Mycol. 2009 Dec;47(8):783-8. doi: 10.3109/13693780902788621. Med Mycol. 2009. PMID: 19343609 Free PMC article.
-
Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.J Biol Chem. 2008 May 23;283(21):14327-34. doi: 10.1074/jbc.M708927200. Epub 2008 Mar 17. J Biol Chem. 2008. PMID: 18347023 Free PMC article.
-
A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis.Mol Biol Cell. 2006 Dec;17(12):5131-40. doi: 10.1091/mbc.e06-08-0701. Epub 2006 Oct 4. Mol Biol Cell. 2006. PMID: 17021252 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials